Linaclotide + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Constipation
Conditions
Functional Constipation
Trial Timeline
Apr 27, 2023 → Jun 9, 2025
NCT ID
NCT05760313About Linaclotide + Placebo
Linaclotide + Placebo is a phase 2 stage product being developed by AbbVie for Functional Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT05760313. Target conditions include Functional Constipation.
What happened to similar drugs?
0 of 6 similar drugs in Functional Constipation were approved
Approved (0) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05760313 | Phase 2 | Completed |
| NCT04026113 | Phase 3 | Completed |
Competing Products
20 competing products in Functional Constipation